Overview We are a clinical stage biotechnology company advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. Our antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of...
Q2 FY2026 — expected 2026-08-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-02 | 2025-12-31 | 0001974640-26-000002 | EDGAR | 96K words |
| 2025-03-03 | 2024-12-31 | 0000950170-25-030385 | EDGAR | — |
| 2024-03-05 | 2023-12-31 | 0001558370-24-002406 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-10 | 2025-09-30 | 0001193125-25-273260 | EDGAR | 62K words |
| 2025-08-11 | 2025-06-30 | 0000950170-25-106234 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0000950170-25-068513 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-124559 | EDGAR | — |
| 2024-08-12 | 2024-06-30 | 0000950170-24-095053 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0001558370-24-007861 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001558370-23-018692 | EDGAR | — |
| 2023-08-28 | 2023-06-30 | 0001558370-23-015278 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-25 | 0001104659-26-034579 | EDGAR | 29K words |
| 2026-03-23 | 0001104659-26-032950 | EDGAR | — |
| 2026-03-02 | 0001974640-26-000001 | EDGAR | — |
| 2026-01-06 | 0001104659-26-001063 | EDGAR | — |
| 2025-11-10 | 0001193125-25-273250 | EDGAR | — |
| 2025-10-10 | 0001104659-25-098487 | EDGAR | — |
| 2025-08-11 | 0000950170-25-106228 | EDGAR | — |
| 2025-07-07 | 0001104659-25-065926 | EDGAR | — |
| 2025-06-23 | 0000950170-25-088600 | EDGAR | — |
| 2025-05-12 | 0001104659-25-046955 | EDGAR | — |
51 total filings indexed. 30 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001974640 |
| Ticker | APGE |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Website | https://www.apogeetherapeutics.com |
| Listed | 2023-07-14 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report